Experiments data further confirmed the relationship between lung cancer immunotherapy resistance and abnormal metabolites while also exploring the regulation of CD8+ T cells and PD-L1 under fat metabolism in lung cancer immunotherapy. Here, CD8A is linked to lung carcinoma.